Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy

19 Jan 2026 CW Team

The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio.

The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary.

This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026.

The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets.

Net proceeds will be utilised towards:

Payment to Viatris for acquisition of Biocon Biologics shares

Repayment of debt linked to the acquisition

Funding for redemption of compulsorily convertible debentures held by Biocon Biologics

General corporate purposes

The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025.

Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Biocon Limited has successfully completed a Qualified Institutions Placement (QIP), raising Rs 4.15 billion (approximately USD 460 million) through the issuance of 12,664,585 equity shares at an issue price of Rs 368.35 per share, including a premium of Rs 363.35. The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio. The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary. This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026. The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets. Net proceeds will be utilised towards: Payment to Viatris for acquisition of Biocon Biologics shares Repayment of debt linked to the acquisition Funding for redemption of compulsorily convertible debentures held by Biocon Biologics General corporate purposes The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025. Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Real Estate

19 Jan 2026

Trident Realty Launches 125-Acre Integrated Township In Panipat

Trident Realty has announced the launch of Trident Parktown, a premium integrated township spread over approximately 125 acres in Sectors 19A and 40, Panipat. Marking the developer’s strategic entry into the city, the project involves a total planned investment of around Rs 12 billion.Phase 1 of Trident Parktown will offer over 400 residential plots, with sizes starting from 200 sq yds. The township is planned as a mixed-use development comprising residential plots, independent floors, group housing, and retail and commercial spaces, aimed at meeting the region’s evolving lifestyle and hou..

Infrastructure Transport

19 Jan 2026

Concord Wins NTPC Order For World’s Largest Hydrogen Locomotive

Concord Control Systems has secured an order from NTPC Limited to develop the world’s largest 3,100 HP hydrogen-fuelled locomotive propulsion system, marking a global first in high-horsepower hydrogen rail technology. The Rs 470 million order has been awarded to Concord’s wholly owned subsidiary, Advance Rail Controls (ARCPL), in collaboration with Railway Engineering Works.The project will convert an existing diesel locomotive into a 3,100 HP hydrogen-powered engine, the highest-ever horsepower conversion globally. Until now, hydrogen rail systems internationally have been limited t..

Real Estate

19 Jan 2026

Signature Global Signs Rs 380 Cr Pact for Seismic Safety Tech

Signature Global has signed a Rs 3.8 billion memorandum of understanding with Indo-Italian joint venture CECO Hirun to implement advanced earthquake-resistance technology across its projects over the next 15 years. The initiative is aimed at strengthening structural safety and occupant comfort in high-rise developments, particularly in seismic-prone regions such as Delhi-NCR, which falls under Seismic Zone IV.As Indian cities continue to grow vertically, buildings are increasingly exposed to dynamic forces including seismic activity, strong winds and temperature variations. To address these ch..